Pfizer Confirms License of Families of Spinal Muscular Atrophy Quinazoline Drug Program from Repligen
Repligen Corporation (NASDAQ: RGEN) announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) to advance Repligen's spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.